Sukhi S Shergill
Overview
Explore the profile of Sukhi S Shergill including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
703
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Orlov N, Muqtadir S, Oroojeni H, Averbeck B, Rothwell J, Shergill S
Psychiatry Res
. 2023 Sep;
317:114908.
PMID: 37732853
Transcranial direct current stimulation (tDCS) of the medial prefrontal cortex (mPFC) is under clinical investigation as a treatment for cognitive deficits. We investigate the effects of tDCS over the mPFC...
2.
Mouchlianitis E, Vanes L, Tracy D, Fett A, Joyce D, Shergill S
Sci Rep
. 2023 Jul;
13(1):11403.
PMID: 37452061
No abstract available.
3.
Mouchlianitis E, Vanes L, Tracy D, Fett A, Joyce D, Shergill S
Sci Rep
. 2023 Jun;
13(1):8938.
PMID: 37268668
Glutamatergic dysfunction is associated with failure to respond to antipsychotic medication in individuals with schizophrenia. Our objective was to combine neurochemical and functional brain imaging methods to investigate glutamatergic dysfunction...
4.
Alpha3/alpha2 power ratios relate to performance on a virtual reality shopping task in ageing adults
Patchitt J, Porffy L, Whomersley G, Szentgyorgyi T, Brett J, Mouchlianitis E, et al.
Front Aging Neurosci
. 2022 Oct;
14:876832.
PMID: 36212034
Background: Aspects of cognitive function decline with age. This phenomenon is referred to as age-related cognitive decline (ARCD). Improving the understanding of these changes that occur as part of the...
5.
Mouchlianitis E, Tracy D, Wigton R, Vanes L, Fett A, Shergill S
BJPsych Open
. 2022 Sep;
8(5):e175.
PMID: 36156189
Background: Conventional pharmacological approaches have limited effectiveness for schizophrenia. There is interest in the application of oxytocin, which is involved in social cognition. Clinical trials have yielded mixed results, with...
6.
Redaelli S, Porffy L, Oloyede E, Dzahini O, Lewis G, Lobo M, et al.
Ther Adv Psychopharmacol
. 2022 Jul;
12:20451253221110014.
PMID: 35833056
Background: The evidence for safe and effective interventions to treat the negative and cognitive symptoms of schizophrenia is lacking. Objectives: Vortioxetine is a novel antidepressant that has been used as...
7.
Porffy L, Mehta M, Patchitt J, Boussebaa C, Brett J, DOliveira T, et al.
J Med Internet Res
. 2022 Jan;
24(1):e27641.
PMID: 35080501
Background: Cognitive deficits are present in several neuropsychiatric disorders, including Alzheimer disease, schizophrenia, and depression. Assessments used to measure cognition in these disorders are time-consuming, burdensome, and have low ecological...
8.
di Hou M, Santoro V, Biondi A, Shergill S, Premoli I
J Psychiatry Neurosci
. 2021 Dec;
46(6):E675-E701.
PMID: 34933940
Background: Transcranial magnetic stimulation can be combined with electromyography (TMS-EMG) and electroencephalography (TMS-EEG) to evaluate the excitatory and inhibitory functions of the cerebral cortex in a standardized manner. It has...
9.
Dunnett D, Oloyede E, Oduniyi O, Arroyo B, Dzahini O, Taylor D, et al.
J Psychopharmacol
. 2021 Oct;
36(2):223-231.
PMID: 34702106
Aim: In this study, we sought to determine clinical outcomes at 1 year for patients prescribed penfluridol in an inner London National Health Service Trust. Using noninterventional data, we describe...
10.
Taub S, Krivoy A, Whiskey E, Shergill S
Expert Opin Drug Saf
. 2021 Sep;
21(4):517-524.
PMID: 34541978
Introduction: Antipsychotic pharmacotherapy is considered a first-line treatment in schizophrenia-related disorders and is associated with favorable prognosis and lower mortality rates. However, low adherence rates present a major clinical challenge....